Dr Peter Hamilton has recently been appointed as Business Lead for Philips Digital Pathology and Image Analysis Belfast. Prior to this and for the last 15 years, he has been Professor of Pathology Imaging and Informatics leading a team of researchers within the Centre for Cancer Research and Cell Biology at Queen’s University Belfast (QUB).
He is also the Founder of PathXL Ltd, a spin out from QUB which established a range of digital pathology software for education, research and clinical applications in pathology. PathXL Ltd was acquired by Philips in 2016. Since starting his academic career 26 years ago, Peter has been leading research on digital pathology, computer vision and tissue bioimaging in diagnostic and molecular cancer pathology for the high throughput quantitative analysis identification of novel tissue and cell biomarkers markers. Being a pioneer of early techniques in tissue measurement, image analysis, pathology informatics and tissue biomarker discovery, he has been published in over 120 peer reviewed publications and generated in access of £15m in grant funding to support pathology research.
Peter established the Digital Pathology Laboratory at QUB with a full range of whole slide scanning technology and associated image analysis software, which is now embedded within the wider Northern Ireland Molecular Pathology Laboratory and an integral component of the Northern Ireland Biobank,which he co-founded. His research programme in recent years has focused on developing new tools for automated tissue microarray analysis, biomarker imaging in colon, breast and prostate cancer supported by EU Framework 7 funding and was the recipient of a £3.7m CRUK Accelerator grant in 2015 for Digital Pathology Accelerator to drive digital pathology standardization and applications in immuno-oncology imaging. Peter took up a full time position with Philips on 1 Sept 2016 whilst retaining an honorary Professorship at QUB.
In summary, Peter has been able to successfully marry an outstanding academic career in pathology with the establishment of a thriving entrepreneurial pathology-based business, translating innovative research into industry and with an opportunity now to lead this field within industry.